Investigational drug · Phase 3
experimental vaccine
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Epidemic Meningitis, Meningococcal Vaccines.
Phase 3Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
963
Any phase or sponsor naming "experimental vaccine"
First trial start
2026
Mar 22, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "experimental vaccine", any sponsor or status.
Conditions studied
As listed on its trial records.
- Epidemic Meningitis
- Meningococcal Vaccines
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "experimental vaccine" as an intervention, largest first.
Sinovac Research and Development Co., Ltd.Industry
NCT04911790 · 131,650 participants · Start Jun 5, 2021 · Primary completion Jan 2, 2023
Drug: Experimental Group · For: COVID-19
Sites: Dali, China
- Safety Study of COVID19 Vaccine on the MarketStatus unknown
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Industry
NCT05890521 · 100,000 participants (planned) · Start Apr 2, 2022 · Primary completion Jun 16, 2022
Drug: Recombinant new coronavirus vaccine (CHO cell) · For: COVID-19
Sites: Changsha, China
- Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui ProvinceStatus unknown
Sinovac (Dalian) Vaccine Technology Co., Ltd.Industry
NCT05470855 · 45,400 participants (planned) · Start Jul 6, 2022 · Primary completion Nov 30, 2022
Drug: Live attenuated varicella vaccine · For: Varicella
Sites: Anqing, China; Chuzhou, China; Fuyang, China · 5 sites in all
- Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and AbovePivotal-lookingCompleted
CanSino Biologics Inc.Industry
NCT04526990 · 44,247 participants · Start Sep 15, 2020 · Primary completion Aug 7, 2021
Drug: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector); Placebo · For: COVID-19
Sites: CABA, Argentina; Canuelas, Argentina; La Plata, Argentina · 74 sites in all
- A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and AbovePivotal-lookingCompleted
China National Biotec Group Company LimitedIndustry
NCT04510207 · 44,101 participants · Start Jul 16, 2020 · Primary completion Jun 16, 2021
Drug: Inactivated SARS-CoV-2 Vaccine (Vero cell); Inactivated SARS-CoV-2 Vaccine (Vero cell) and 1 more · For: COVID-19
Sites: Sanābis, Bahrain; Cairo, Egypt; Amman, Jordan · 6 sites in all
- A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and OlderPivotal-lookingCompleted
CureVacIndustry
NCT04652102 · 39,680 participants · Start Dec 11, 2020 · Primary completion Jun 10, 2022
Drug: CVnCoV; Placebo and 1 more · For: Covid19; SARS-CoV-2
Sites: Buenos Aires, Argentina; Mar del Plata, Argentina; Rosario, Argentina · 46 sites in all
- A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)Pivotal-lookingCompleted
WestVac Biopharma Co., Ltd.Industry
NCT04904471 · 39,663 participants · Start Jun 15, 2021 · Primary completion Jan 31, 2022
Drug: Recombinant COVID-19 vaccine (Sf9 cells) · For: COVID-19
Sites: Bekasi, Indonesia; Malang, Indonesia; Surabaya, Indonesia · 24 sites in all
HealthPartners InstituteAcademic, hospital or other
NCT07735767 · 36,245 participants · Start Jan 2014 · Primary completion Dec 2022
Drug: Tetanus Toxoid, acellular pertussis, diphtheria toxoid · For: Pertussis Vaccines
- The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19Pivotal-lookingStatus unknown
Chinese Academy of Medical SciencesAcademic, hospital or other
NCT04659239 · 34,020 participants (planned) · Start Jan 28, 2021 · Primary completion Sep 2021
Drug: Inactivated SARS-CoV-2 Vaccine (Vero cell); Placebo · For: COVID-19
Sites: São Bernardo do Campo, Brazil; Sungai Buloh, Malaysia
- Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and AdolescentsCompleted
Sinovac Life Sciences Co., Ltd.Industry
NCT04992208 · 31,041 participants · Start Jul 24, 2021 · Primary completion Mar 24, 2023
Drug: Experimental Group · For: COVID-19
Sites: Dali, China
Newest research
PubMed records naming it or its code names, newest first.
- Influenza viruses as vaccine vectors: Historical background and future directions.
Isakova-Sivak I, Matyushenko V, Rudenko L · Virology 2027
- Progress toward HIV-1 subtype C vaccines: understanding antiviral immune mechanisms and viral adaptation.
Williamson AL, Rybicki EP · Expert Rev Vaccines 2026
- A single-cycle, recombinant VSV platform Nipah vaccine cross-protects against Hendra virus in nonhuman primates.
Pigeaud DD, Borisevich V, Turcinovic J, et al. · PLoS Pathog 2026
- Protective and immunostimulatory effects of a vitellogenin functional domain-based vaccine in Atlantic salmon against Caligus rogercresseyi.
Casuso A, Rodríguez-Gabilondo A, Leal Y, et al. · Vaccine 2026
- Immunogenic cell death as a promising platform for adjuvant development.
Adachi T, Kuroda E · Curr Opin Virol 2026
- Ethical challenges in outbreak trial design: from Ebola to Nipah.
Jamrozik E, Abeler-Dörner L, Chaudhari A, et al. · Vaccine 2026
Also in development for Epidemic Meningitis
- Active Comparator vaccinePhase 36 trials
Sinovac Biotech Co., Ltd · Epidemic Meningitis, Meningococcal Vaccines, Herpes Zoster
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.